Laurent CONTAUT

French citizenship
Date Of Birth : June 20th 1974 (Toulouse, France)
International driving license
Married
Email : laurentcontaut@hotmail.com
Cell phone number : +33 (0) 7 80 00 96 07
Address : 13 rue d’Armor, 29400 Plougourvest - France

C-LEVEL EXECUTIVE LEADER

POSITIONS HELD
April 2022, on going : CLLC Consulting (Roscoff – Brittany, France)
Managing Director
Acting as a Consultant in R&D, partnering with biotech / pharma / medtech companies with special focus on :
- company organizational structuring or restructuring
- HR support including recruitment of new staff
- Creation of highly performing drug development teams
- Enhancement of governance and operating models / program leadership
- Fund raising activities
- Support to sign-off strategic partnerships and out-licensing agreements
- SOPs creation, improvement and simplification
- clinical development strategy / Go-to-market strategy
- CROs / vendors selection and management
- Inspection / audit readiness activities
- Support for North American / Asian firms to set up offices / activities in Europe

November 2020 to March 2022 : PEACCEL (Paris, France)

CEO
Creation of the new PEACCEL organizational structure
Define company’s vision and strategy
Lead the team (8 persons) / attract and retain top talents
Lead the fundraising activities / Liaise with investors, VCs and key customers worldwide
General management of the company

June 2018 to September 2020 : NEUROTRIALS, Brain and Spine Institute (Paris, France)
Head – NEUROTRIALS, Early Clinical Development Unit
Creation of this new entity (niche CRO) and especially of the organizational structure
Recruitment and line management of the team members (team of 7 persons)
General management of NEUROTRIALS, early clinical development unit of the ICM, specialized in phase 2a clinical studies in Nervous System
Therapeutic areas : neurology / psychiatry and oncology

April 2015 to April 2018 : NoNO Inc (Toronto, Canada)

Vice President, Clinical Development
Full reorganization of the company structure and line management of a team of 15 persons
Assist the CEO with providing overall strategy and direction of company operations, processes and procedures
In charge of the Clinical Development department
Liaise with Key Opinion Leaders, Principal Investigators, Clinical Advisors, Safety Committees
Participate in writing grants to improve research and development activities
Lead the fundraising activities on behalf of the Company and in negotiating grants, contracts and various agreements with other parties
Therapeutic areas : neurology (stroke and Alzheimer’s disease), Trauma Brain Injury and pain
March 2013 to March 2015 : Merck Serono (Beijing, China)
Head of Global Clinical Operations China
Line management of 45 people in the Beijing, Shanghai and Guangzhou offices
Accountable for the delivery of all China-based clinical programs and trials (from phase I to phase IV) on time, budget and quality on behalf
of Global Clinical Operations (GCO)
Implementation of a new operating model in China (Strategic Partnership with Quintiles)
Senior Oversight of clinical trials from both internal projects and external collaborations. Participation to due diligence activities
Ensure that all functional activities within GCO China are performed to meet the defined timelines, budget and quality
Therapeutic areas : oncology, neurology, endocrinology, immunology and fertility

January 2012 to February 2013 : Quintiles (Singapore)

Director, Clinical Program Management
Line management and operational management of 8 Clinical Project Managers across Asia Pacific
Manage staff in accordance with organization's policies and applicable regulations
Work with the Clinical Project Managers to ensure that project budgets meet financial and company goals
Act as the key relationship program director for assigned clients (American, Japanese and South Korean sponsors)
Provide consultation to clients on drug development process, strategy, and plans as needed
Therapeutic areas : rheumatology, oncology, neurology and dermatology with special focus on biosimilars

November 2006 to December 2011 : Merck Serono (Geneva, Switzerland)

Associate Director, Global Clinical Program Manager
Program Director for all clinical trials using the product Rebif in neurology (from FIH / phase I to phase IV)
Lead and coordination of all different operational Life Cycle Management activities of this program
Operational management of 10 Clinical Trials Leaders worldwide
Accountable for planning and execution of trials, deliverables, timelines, resources, and budget for the Rebif program
Co-Leader of the Rebif Global Clinical Development Team
CROs selection, management and surveillance
Contribution to Target Product Profile, Global Strategic Plan, Global Regulatory Plan and Clinical Development Plans
Participation to Health Authorities consultations (Briefing Books writing) and core member of the submissions team
Leader of the RNF Task Force One which mission was to increase chances of success of the RNF regulatory submissions. Mission
accomplished as EMA approval was granted for the CIS indication in December 2011
Member of the Task Force Asia Strategy which mission was to develop the company strategy on the Asian market
4 months spent in the Beijing office to help to define the long-term strategy from a clinical operations perspective
Therapeutic areas : oncology, endocrinology, fertility and special focus on neurology

Senior Clinical Project Manager / Clinical Trial Leader (till August 2008)
Management of two international phase III studies in patients at high risk of converting (CIS, pre-Multiple Sclerosis) to Multiple Sclerosis. The
project budget was 80 million USD and the studies were performed in 32 countries worldwide. The investigational drug was Rebif New
Formulation (interferon beta 1a)

September 2004 to August 2006 : Genzyme (Cambridge, UK)

International Clinical Project Manager
Management of an international phase III study on C Difficile Associated Diarrhea. The study was performed in Australia, Austria, Belgium,
Canada, Czech Republic, Denmark, France, Germany, Ireland, Italy, Norway, Spain, Sweden, Switzerland, the UK and the US. The
investigational drug was a polymer called tolevamer (binding compound against C Difficile toxins). Goal was to enroll 520 patients over a 24
month recruitment period, 150 investigators sites
Participation to the relocation of the clinical operations headquarters of Genzyme from the Netherlands to the UK
Therapeutic area : infectious diseases

November 2002 to August 2004 : Protein Design Labs (Paris, France)

Study Manager
Management and coordination of 3 international studies (1 phase I and 2 phase II) in Crohn’s disease and Ulcerative Colitis in Austria, Belgium
Bulgaria, Croatia, Germany, Hungary, Russia, Slovakia, the Netherlands and the UK.
The investigational drugs were humanized monoclonal antibodies : anti-gamma interferon , anti-CD25 and anti-CD3
Evaluation of new indications for these monoclonal antibodies (lupus, psoriasis, rheumatoid arthritis, etc.)
CROs / CRAs manager / Datafax (data capture software) specialist
Creation of European clinical operations headquarters in France in collaboration with the Medical Director
In the frame of the company exchange program, I spent 3 months in San Francisco in 2004; I continued managing the European part of the
clinical trials from the company headquarters. In addition, I worked very closely with the Global Program Team in the management of the North
American part of the clinical studies
Therapeutic areas : gastroenterology, immunology, rheumatology and dermatology

May 2000 to October 2002 : Ingenix (Paris, France)

Insourcing Manager
Recruitment of new employees, line management of a team of 25 persons (CRAs, lead CRAs, Clinical Project Managers), relationships and
contracts negotiation with pharmaceutical / biotech companies (business development) and with medias

June 1998 to April 2000 : Quintiles (Paris, France)

CRA
International phase III studies : start-up, sites selection, initiation, monitoring and close-out. Participation to several feasibility studies
Therapeutic areas : dermatology, cardiology (medical device)

April 1997 to May 1998 : Rhone Poulenc Rorer laboratories (Paris, France)
CRA
International phase II and III studies. Start-up of the study, sites selection, initiation, monitoring and close-out. Participation to the protocols
writing and CRFs design
Therapeutic areas : respiratory and oncology

EDUCATION
1997 Master’s Degree in Healthcare Engineering (“IUP Ingénierie de la Santé”)
University of pharmacy (Montpellier, France)

1994 Two-year undergraduate diploma in Life Sciences (“DEUG B”)

University of Paul Sabatier (Toulouse, France)

LANGUAGES
French : mother tongue
English : fluent
German : basic notions

AWARDS
CEO of the Year 2021 (awarded by AI Global Media Ltd, UK)

MISCELLANEOUS
Participation to and presentation at several congresses worldwide :
DDW in Orlando, USA (2003)
DDW in New Orleans, USA (2004)
UEGW in Madrid, Spain (2003)
DFUG in Lake Louise, Canada (2004)
ECTRIMS in Prague, Czech Republic (2007) / ECTRIMS in Gothenburg, Sweden (2010)
ECTRIMS /ACTRIMS / LACTRIMS in Montreal, Canada (2008)
ARDDS in Shanghai, China (2014）
AFSOS in Paris, France (2019)
Cann2019 in London, UK (2019)
IACM in Berlin, Germany (2019)
Jefferies conference, London (2022)

Several business or personal trips in Australia, Austria, Argentina, Belgium, Bosnia, Bulgaria, Canada, China, Colombia, Croatia, Czech
Republic, Denmark, Germany, Greece, Hungary, Indonesia, Italy, Iran, Japan, Lebanon, Luxembourg, Malaysia, Monaco, the Netherlands,
Portugal, Philippines, Romania, Russia, Singapore, Slovakia, Slovenia, South Korea, Spain, Switzerland, Sweden, Thailand, Tunisia, the United
Kingdom and the USA

Hobbies : Sports, painting, travels

“PROFILE”
✓ More than twenty-five years of international experience working in the Life Sciences / Healthcare space with strong focus on the fields
of pharma / biotech / medtech

✓ Expertise in general management, recruitment, people and resources management, budget management (P&L), regulatory and drug
development strategy, business development and due diligence activities, clinical trial / program management, CRO management /
oversight and training / coaching / mentoring of people and in Artificial Intelligence

✓ Employed by different kind of companies / entities : start-ups, CROs, small biotech firms, mid-size / large pharmaceutical companies
and academic institutions

✓ Working from different locations on all major markets (USA, EU, Switzerland, Japan, Canada, Australia and Emerging Markets)

✓ Experience in clinical development activities and strategic development of products worldwide, in all phases of the pharmaceutical
development (I, II, III and IV) as well as pre-clinical activities and post-marketing

✓ Involved in regulatory consultations and in submissions of dossiers to Health Authorities worldwide (with strong and special focus on
FDA, Health Canada, EMA, Swissmedic, C FDA, K FDA, PMDA and TGA)

✓ Therapeutic areas experience includes oncology, neurology, psychiatry, immunology, dermatology, gastroenterology, infectious
diseases, respiratory, pain, inflammation and rheumatology

✓ Participation to due diligence activities : e.g BeiGene, Mitsubishi Tanabe Pharma, Hutchinson, etc …

✓ Experience working with :

- chemical entities, biologics, biosimilars, phytotherapeutics and medical devices
- murine, humanized and human monoclonal antibodies
- new drug formulations (long-acting, slow-release, de-immunized, etc) : pegylation, nanotechnology, etc.

✓ Strong global expertise in line management and in operational management of small and large teams

✓ Able to drive international teams to deliver high quality results, on time and within the allocated budgets

✓ Expertise in creating and changing company organizational structure

✓ Experience in selecting and managing CROs / vendors and ensure quality plus timely deliverables within the allocated budgets. Able
to provide directions to CROs / vendors and define / follow up on KPIs

✓ Expertise in creating and implementing innovative operating models / strategic partnerships

✓ Ability to create / develop SOPs. Can establish function-specific SOPs / processes that facilitate productivity

✓ Experience in the opening or the relocation of company headquarters worldwide

✓ Robust expertise in P&L management

✓ Strong experience in fundraising activities (up de 25 million USD)

✓ Team player with solid experience working across the matrix and with internal / external stakeholders

✓ Passionate, curious, highly energetic and motivated leader with a strong team spirit

✓ Creative, innovative and open-minded

✓ Solid communicator

✓ Excellent judgment and problem-solving attitude

✓ Strong leadership skills, able to engage people. Generates trust within teams

✓ Adaptable, flexible, fast learner with a positive attitude

✓ Excellent organizational skills and able to prioritize / multi-task

✓ Diplomatic, pragmatic, results-oriented and able to deliver high quality under pressure.